Stock Earnings

Question 1

What are Alnylam Pharmaceuticals Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Alnylam Pharmaceuticals Inc has a total asset of $4,239, Net loss of $-278

Question 2

What are the key financial ratios for ALNY?

Accepted Answer

Alnylam Pharmaceuticals Inc's Current ratio is 1.01, has a Net margin is -12.36, sales per share of $17.61.

Question 3

How is Alnylam Pharmaceuticals Inc's revenue broken down by segment or geography?

Accepted Answer

Currently Alnylam Pharmaceuticals Inc data is not available.

Question 4

Is Alnylam Pharmaceuticals Inc profitable?

Accepted Answer

no, according to the latest financial statements, Alnylam Pharmaceuticals Inc has a net loss of $-278

Question 5

Does Alnylam Pharmaceuticals Inc have any liabilities?

Accepted Answer

yes, Alnylam Pharmaceuticals Inc has liability of 4,172

Question 6

How many outstanding shares for Alnylam Pharmaceuticals Inc?

Accepted Answer

Alnylam Pharmaceuticals Inc has a total outstanding shares of 129.29

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	3,210	2,248	1,828	1,037	844	492
Revenue Growth (YoY)	53%	23%	76%	23%	72%	125%
Cost of Revenue	516	323	310	168	140	78
Gross Profit	2,693	1,924	1,517	868	704	414
Selling, General & Admin	1,180	975	795	770	620	588
Research & Development	1,247	1,126	1,004	883	792	654
Operating Expenses	2,428	2,101	1,800	1,653	1,412	1,243
Other Non Operating Income (Expenses)	0	-6	-17	-6	-19	45
Pretax Income	-31	-377	-433	-1,127	-852	-855
Income Tax Expense	-75	-99	6	4	0	2
Net Income	43	-278	-440	-1,131	-852	-858
Net Income Growth	-112.99%	-37%	-61%	33%	-1%	-3%
Shares Outstanding (Diluted)	137.34	127.65	124.9	121.7	118.5	115
Shares Change (YoY)	7%	2%	3%	3%	3%	5%
EPS (Diluted)	0.31	-2.17	-3.52	-9.3	-7.2	-7.46
EPS Growth	-112%	-38%	-62%	28.99%	-3%	-8%
Free Cash Flow	221	-42	41	-613	-718	-685
Free Cash Flow Per Share	1.6	-0.32	0.32	-5.03	-6.05	-5.95
Gross Margin	83.89%	85.58%	82.98%	83.7%	83.41%	84.14%
Operating Margin	8.22%	-7.82%	-15.42%	-75.69%	-83.88%	-168.29%
Profit Margin	1.33%	-12.36%	-24.07%	-109.06%	-100.94%	-174.39%
Free Cash Flow Margin	6.88%	-1.86%	2.24%	-59.11%	-85.07%	-139.22%
EBITDA	320	-120	-228	-741	-661	-794
EBITDA Margin	9.96%	-5.33%	-12.47%	-71.45%	-78.31%	-161.38%
D&A For EBITDA	56	56	54	44	47	34
EBIT	264	-176	-282	-785	-708	-828
EBIT Margin	8.22%	-7.82%	-15.42%	-75.69%	-83.88%	-168.29%
Effective Tax Rate	241.93%	26.25%	-1.38%	-0.35%	0%	-0.23%

Alnylam Pharmaceuticals Inc (ALNY) Price